NICE rejects Venclexta (venetoclax) as a treatment for chronic lymphocytic leukemia.- AbbVie + Roche
The National Institution for Health and Care Excellence (NICE) has in its first draft guidance rejected Venclexta (venetoclax) from AbbVie + Roche as a treatment for Chronic Lymphocytic Leukaemia (CLL) as it finds there are too many uncertainties in its clinical evidence base and it is supported by a small study. Venclexta has a price of £4,800 a month and at this level was not found cost effective.
Moreover, patients with the 17P deletion or TP53 mutation have alternative treatments available as NICE has recommended Gilead’s Zydelig (idelalisib) in first line treatment and Imbruvica (ibrutinib) from AbbVie/Janssen in second line for this type of cancer. NICE also decided the drug should not be reimbursed via the revised Cancer Drugs Fund to allow for more conclusive clinical evidence to be produced.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins